Pharma Pulse: J&J Enters TrumpRx and the Red Flags in Pediatric Vaccines

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• Johnson & Johnson has officially joined the TrumpRx initiative, the direct-to-patient platform designed to bypass PBMs and offer "most-favored-nation" drug pricing. By participating, J&J secures an exemption from pharmaceutical tariffs while moving toward price parity with European markets. This follows J&J's announcement of a $55 billion domestic investment, including new state-of-the-art manufacturing sites in North Carolina and Pennsylvania.
• Turning to public health, a new study in JAMA reveals a troubling post-pandemic trend: the rate of children missing their MMR vaccine by age two rose to nearly 8% in 2024. Researchers identified a critical "red flag": infants who are late for their 2- and 4-month routine shots are seven times more likely to miss the MMR dose entirely.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.